Showing 1 - 10 of 27 Gland and Hormone Related Diseases
Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator: Adrienne New

Phone: 713.441.3250

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

3D Breast Implant

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Breast implants are the most common way of rebuilding the shape of the breasts after breast cancer surgery. However, current breast implants cannot completely match individual differences in breast shape. It is also often difficult to match the ... Read more >

A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator: Adrienne New

Phone: 713.441.3250

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti ... Read more >

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Minh Truong

Phone: 346.238.6403

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >

A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy

Status: Enrolling

Investigator: Sandra Templeton

Study Coordinator: Erick Villarreal-Williams

Phone: 346.238.5594

This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes th ... Read more >

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Jose Cruz

Phone: 713.441.4457

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor (HER2)-amplified BC. An open label Phase 1b clinical study (REP0111) is ongoing (enrollment completed) in fi ... Read more >

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Minh Truong

Phone: 346.238.6403

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >

Acupuncture Trial

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Minh Truong

Phone: 346.238.6403

A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ≥3 months after the cancer treatment is comp ... Read more >

Ad5-SGE-REIC in prostate cancer

Status: Open Not Enrolling

Investigator: Brian Miles

Study Coordinator: Vivian MacDonnell

Phone: 714.441.8113

This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >

BAY94-8862-16244 (Finerenone) - FIDELIO

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

BAY94-8862-17530 (Finerenone) - FIGARO

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Clinical Phase Ib/II Trial of L-NMMA Plus Docetaxel in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Jose Cruz

Phone: 713.441.4457

The reason for this trial is to compare DS-8201a to other treatments being used for HER2-low breast cancer that has spread to other parts of the body. DS-8201a is a new medicine for breast cancer that has not been approved yet by the Food and ... Read more >

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Jose Cruz

Phone: 713.441.4457

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. ... Read more >

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Jose Cruz

Phone: 713.441.4457

Primary Objective: • To compare the efficacy of DS-8201a to investigator’s choice by means of progression-free survival (PFS). Secondary Objectives: • To further investigate the efficacy of DS-8201a compared to investigator’s choice on: − ... Read more >

GILEAD GS-US-223-1017

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

To evaluate whether selonsertib (SEL) can slow the decline in kidney function, reduce the risk of kidney failure, or reduce the risk of death due to kidney disease in subjects with diabetic kidney disease (DKD) ... Read more >

KOWA K-877-302

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

In patients with diabetes and high triglycerides, subjects will be given pemafibrate to help reduce triglycerides level and cardiovascular outcomes. ... Read more >

Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer. ... Read more >

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2

Status: Open Not Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Phase Ib/II Study of Leronlimab (PRO 140) Combined with Carboplatin in Patients with CCR5+ Metastatic Triple-Negative Breast Cancer (mTNBC)

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastati ... Read more >

Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy.

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Denesha Potts

Phone: 713.441.6011

This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >

Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer

Status: Open Not Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting el ... Read more >

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Minh Truong

Phone: 346.238.6403

This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >

Live Chat Available